Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.
Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China.
Trends Mol Med. 2021 Mar;27(3):207-219. doi: 10.1016/j.molmed.2020.10.004. Epub 2020 Nov 13.
Immune checkpoints negatively regulate immune cell responses. Programmed cell death protein 1:programmed death ligand 1 (PD-1:PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4):B7-1 are among the most important immune checkpoint pathways, and are key targets for immunotherapies that seek to modulate the balance between stimulatory and inhibitory signals to lead to favorable therapeutic outcomes. The current dogma of these two immune checkpoint pathways has regarded them as independent with no interactions. However, the newly characterized PD-L1:B7-1 ligand-ligand cis-interaction and its ability to bind CTLA-4 and CD28, but not PD-1, suggests that these pathways have significant crosstalk. Here, we propose that the PD-L1:B7-1 cis-interaction brings novel mechanistic understanding of these pathways, new insights into mechanisms of current immunotherapies, and fresh ideas to develop better treatments in a variety of therapeutic settings.
免疫检查点负向调节免疫细胞的反应。程序性死亡蛋白 1(PD-1):程序性死亡配体 1(PD-L1)和细胞毒性 T 淋巴细胞相关蛋白 4(CTLA-4):B7-1 是最重要的免疫检查点途径之一,也是免疫疗法的关键靶点,这些疗法旨在调节刺激和抑制信号之间的平衡,从而产生有利的治疗效果。目前,关于这两条免疫检查点途径的观点一直认为它们是相互独立的,没有相互作用。然而,新发现的 PD-L1:B7-1 配体-配体顺式相互作用及其与 CTLA-4 和 CD28 结合的能力,但不能与 PD-1 结合,表明这些途径有显著的串扰。在这里,我们提出 PD-L1:B7-1 顺式相互作用为这些途径提供了新的机制理解,为当前免疫疗法的机制提供了新的见解,并为在各种治疗环境中开发更好的治疗方法提供了新的思路。